Planned Parenthood plans to withdraw from Title X program, amid looming Trump Administration rule changes; a new cure accepted by the FDA for a deadly strain of tuberculosis has been found to have a 90% success rate in a patient trial; opioid distribution to patients has began to change amongst doctors with new recommendations based around set prescribing levels.
Planned Parenthood announced Wednesday it will soon leave Title X, the federal family planning program, barring a court decision to delay Trump administration rules that bar clinics from referring patients for abortions, Associated Press reported. HHS stated the agency's willingness to accommodate clinics that are making efforts to comply with upcoming rule changes, but Planned Parenthood's spokeswoman Erica Sackin stated the organization’s intent to leave the program, due to regulations set to take effect September 18.A small trial consisting of 109 patients has shown a groundbreaking success rate of 90% against a deadly strain of drug-resistant tuberculosis. This particular XDR strain is involved in about 30,000 cases in over 100 countries, with a cure rate of only 34%. The New York Times reported that the FDA has endorsed the new approach by approving the use of 3 pills: pretomanid, bedaquiline, and linezolid. The treatment can soon come into use worldwide. Narcotic prescriptions have been reduced by nearly one-third since October 2017, after growing concern about the opioid crisis, Kaiser Health News reports. Surgeons stated the transition of narcotic prescriptions have changed dramatically since the beginning of their careers as there was little or no information recommended to them about pill distribution to patients after procedures. The Michigan OPEN guidelines now recommends for no more than 10 pills, equivalent to 5 mg of oxycodone, for an operation such as a minor hernia repair, as opposed to the 29 pills prescribed in the past.
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen
Report Reveals Mounting Burdens of Drug Shortages on US Health System
June 27th 2025Vizient's 2024 survey reveals a sharp rise in drug shortages across US health care, with pediatric care hit especially hard and labor costs soaring—but the true impact may go far beyond limited medication access, threatening to disrupt the very foundations of how health systems operate.
Read More